Home > Name List By t > Teniposide Canada

CAS No 29767-20-2 , Teniposide Search by region : Canada

  • Name: Teniposide
  • CAS Registry Number:
  • Melting Point: 274 - 277
  • Boiling Point: 864
  • Density: 1.59 g/cm3
  • Refractive index: 1.697
  • Safety Statements: Poison by intraperitoneal and subcutaneous routes. An experimental teratogen. Human systemic effects by ingestion and intravenous route: anorexia, nausea or vomiting, leukopenia, agranulocytosis and aplastic anemia of the blood, bone marrow changes, and hair changes. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of SOx.
  • Hazard Symbols: Xi
  • EINECS: 249-831-2
  • Molecular Weight: 656.66
  • InChI: InChI=1/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31?,32-/m0/s1
  • Risk Statements: 36/37/38
  • Molecular Formula: C32H32O13S
  • Molecular Structure:CAS No:29767-20-2 Teniposide

Related products

Select to

29767-20-2 TENIPOSIDE

  • Canada Synth?se AptoChem Inc. [Manufacturer]
  • Tel: 514-496-4252
  • Fax: 514-496-4253
  • Address: Synth?se AptoChem Inc.
    6100 Royalmount Ave
    Montreal, QC
    Canada
    H4P 2R2 null,nullCanada
Contact Supplier

Select to

1/1
References of Teniposide
Title: Teniposide
CAS Registry Number: 29767-20-2
CAS Name: (5R,5aR,8aR,9S)-5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-b-D-glucopyranosyl]oxy]furo[3￠,4￠:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
Synonyms: 4￠-demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-b-D-glucopyranoside); 4￠-demethylepipodophyllotoxin-b-D-thenylidine glucoside; ETP
Manufacturers' Codes: NSC-122819; VM-26
Trademarks: Vehem-Sandoz (Sandoz); Vumon (BMS)
Molecular Formula: C32H32O13S
Molecular Weight: 656.65
Percent Composition: C 58.53%, H 4.91%, O 31.67%, S 4.88%
Literature References: Semi-synthetic derivative of podophyllotoxin, q.v. Prepn: A. Von Wartburg, ZA 6607585; C. Keeler-Juslen et al., US 3524844 (1968, 1970 both to Sandoz). Mechanism of action: H. St?hlen, Eur. J. Cancer 6, 303 (1970). Pharmacology: M. Hacker, D. Roberts, Cancer Res. 37, 3287 (1977); S. M. Sieber et al., Teratology 18, 31 (1978); T. J. Vietti et al., Cancer Treat. Rep. 62, 1313 (1978). Metabolism: L. Allen, Drug Metab. Rev. 8, 119 (1978); Cancer Res. 38, 2549 (1978). Clinical studies: N. M. Gadel-Mawla et al., Cancer Treat. Rep. 62, 993 (1978); R. E. Bellet et al., ibid. 445. Studies on delayed toxicity in mice after i.p. injections: M. Hacker, D. Roberts, Cancer Res. 35, 1756 (1975); H. St?hlin, Eur. J. Cancer 12, 925 (1976). Review of pharmacology, pharmacokinetics and assay methods: P. I. Clark, M. L. Slevin, Clin. Pharmacokinet. 12, 223-252 (1987). Comprehensive description: J. J. Kettenes-van den Bosch et al., Anal. Profiles Drug Subs. 19, 575-600 (1990).
Properties: Crystals from abs ethanol, mp 242-246°. [a]D20 -107° (9:1 chloroform/methanol). uv max (methanol): 283 nm (E1%1cm 64.1). pKa 10.13.
Melting point: mp 242-246°
pKa: pKa 10.13
Optical Rotation: [a]D20 -107° (9:1 chloroform/methanol)
Absorption maximum: uv max (methanol): 283 nm (E1%1cm 64.1)
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Alkaloids/Natural Products; Podophyllum Derivatives; Topoisomerase II Inhibitor.